Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Recommendation of "Hold" by Analysts

Key Points

• Ironwood Pharmaceuticals has received a consensus recommendation of "Hold" from seven brokerages, with a twelve-month price objective averaging $4.94.
• The company's stock saw a notable increase of 10.9% following the latest earnings report, where it achieved $0.14 EPS, beating analysts' expectations.
• Institutional investors are actively engaging with Ironwood Pharmaceuticals, with several firms significantly increasing their stakes, including a 47.4% increase by Deutsche Bank AG.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) has earned an average rating of "Hold" from the seven brokerages that are presently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $4.94.

A number of brokerages have recently issued reports on IRWD. Craig Hallum cut shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. Wall Street Zen raised shares of Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 9th.

Ironwood Pharmaceuticals Stock Up 10.9%

IRWD opened at $1.09 on Thursday. The firm has a 50 day moving average price of $0.76 and a 200-day moving average price of $1.13. Ironwood Pharmaceuticals has a twelve month low of $0.53 and a twelve month high of $5.21. The stock has a market capitalization of $176.38 million, a price-to-earnings ratio of -21.80 and a beta of 0.33.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its earnings results on Thursday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. The business had revenue of $85.24 million during the quarter, compared to analysts' expectations of $62.02 million. As a group, analysts expect that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG increased its position in Ironwood Pharmaceuticals by 47.4% during the 4th quarter. Deutsche Bank AG now owns 1,567,535 shares of the biotechnology company's stock valued at $6,944,000 after purchasing an additional 504,336 shares during the period. Tower Research Capital LLC TRC increased its position in Ironwood Pharmaceuticals by 1,130.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 17,521 shares of the biotechnology company's stock valued at $78,000 after purchasing an additional 16,097 shares during the period. GSA Capital Partners LLP increased its position in Ironwood Pharmaceuticals by 3,683.6% during the 1st quarter. GSA Capital Partners LLP now owns 524,676 shares of the biotechnology company's stock valued at $771,000 after purchasing an additional 510,809 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Ironwood Pharmaceuticals during the 4th quarter valued at about $1,888,000. Finally, Cerity Partners LLC purchased a new position in Ironwood Pharmaceuticals during the 1st quarter valued at about $142,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.